The Latest Breaking News from LLY

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

Dow Jones futures rose, but be wary after the stock market suffered another week of solid losses as fears grew of a "hard" economic landing.

Eli Lilly and Albemarle lead five stocks that have shown resilience amid the sell-off and may be poised to lead the way forward.

The stock market tumbled Wednesday on a hot inflation report. A lack of investor fear suggests no market bottom yet.

Eli Lilly is the IBD Stock Of The Day after "transformative" data in obesity helped LLY stock retain its recent breakout.

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).  Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval.  The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

The market correction suffered a violent sell-off late in the week. Apple is a relative winner but an absolute loser.

With several core products showing strength, along with their Covid-19 antibodies, Eli Lilly updated their 2022 EPS guidance.

Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 9.8% on an annualized basis producing an average annual return of 21.54%. Currently, Eli Lilly has a market capitalization of $276.68 billion.